SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against SelectQuote (NYSE: SLQT) after the U.S. Department of Justice (DOJ) announced it was intervening in a separate lawsuit against the company. The news of the DOJ's involvement caused a significant 19% drop in SelectQuote's stock price on May 1, 2025. The class action, known as Pahlkotter v. SelectQuote, Inc. et al., No. 1:25-cv-06620 (S.D.N.Y.), seeks to represent investors who bought or otherwise acquire ...

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during a specified class period [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including its gene therapy product, ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, inadequate trial protocols to detect severe side effects, and the potential for adverse events to halt clinical trials and regulatory approvals [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock price drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [8].

Core Viewpoint - West Pharmaceutical Services, Inc. is facing a federal securities class action due to disappointing revenue and earnings forecasts, attributed to operational challenges and customer losses during the Class Period from February 16, 2023, to February 12, 2025 [1][3]. Group 1: Financial Performance and Forecasts - On February 13, 2025, West issued weak revenue and earnings forecasts for 2025, citing challenges including the loss of two major continuous glucose monitoring (CGM) customers transitioning to in-house manufacturing [3]. - The company's share price dropped by approximately 38%, from $322.28 on February 12, 2025, to $199.11 on February 13, 2025, following the announcement [3]. Group 2: Allegations in the Class Action - The complaint alleges that West failed to disclose significant destocking issues in its high-margin HVP portfolio, contrary to claims of strong visibility into customer demand [4]. - It is claimed that the SmartDose device, positioned as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [4]. - The margin pressures faced by West raised concerns about potential costly restructuring activities, including exiting CGM contracts with long-standing customers [4].

Core Viewpoint - A class action lawsuit has been filed against Open Lending Corp. due to significant financial losses reported by the company, impacting investors who purchased stock between February 24, 2022, and March 31, 2025 [1]. Financial Performance - Open Lending postponed its earnings release and conference call on March 17, 2025, and requested additional time to complete its annual 10-K report, leading to a 9.3% drop in share price to $3.91 [2]. - On March 31, 2025, Open Lending reported a net loss of $144 million, attributed to the deterioration of prior loan vintages, elevated delinquencies and defaults, and increased income tax expenses [3]. - Following the loss announcement, Open Lending's stock plummeted nearly 58%, closing at $1.17 per share [4]. Legal Actions - Investors who purchased Open Lending stock during the specified class period and incurred losses are encouraged to contact the law firm Barrack, Rodos & Bacine regarding their rights and the potential for leading the class action lawsuit [5]. - The deadline for investors to submit a motion to be appointed as lead plaintiff is June 30, 2025, although participation in any recovery does not require serving as lead plaintiff [6]. Law Firm Background - Barrack, Rodos & Bacine has over 40 years of experience in prosecuting securities law class actions, achieving significant recoveries for investors in high-profile cases [7].

Core Viewpoint - Fluence Energy, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed product defects that have led to significant financial losses for investors [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit against Fluence Energy involves purchasers of its Class A common stock from October 28, 2021, to February 10, 2025, with a deadline of May 12, 2025, for seeking lead plaintiff status [1]. - The lawsuit alleges that Fluence Energy and its executives violated the Securities Exchange Act of 1934 by making false statements regarding the quality and performance of their energy storage products [3][4]. - Specific allegations include defective design and operational issues with products, failure to address known defects, and overstated efficacy and safety claims [3]. Group 2: Financial Impact and Stock Performance - Following the revelation of defects in the Diablo project, Fluence Energy's stock price dropped over 15% [4]. - A subsequent report by Blue Orca Capital led to an additional decline of more than 13% in stock price due to allegations of premature technology sales and a lawsuit from Siemens Energy Inc. for fraud and design failures [5]. - In November 2024, Fluence Energy's stock fell approximately 22% after the company reported that only 65% of its fiscal 2025 revenue guidance was backed by current contracts, indicating a need for new orders [6]. - The company further reduced its fiscal 2025 revenue guidance by about $600 million in February 2025, resulting in a significant stock price drop of over 52% [7]. Group 3: Company Background - Fluence Energy is a global provider of energy storage products and services, focusing on renewable energy solutions [2].

Core Viewpoint - A class action lawsuit has been filed against Napco Security Technologies, Inc. for allegedly misleading investors about its growth projections and sales performance during the specified period [1][2]. Allegations - The lawsuit claims that Napco failed to disclose its true ability to forecast product demand and its negotiating position with distributors, leading to inflated long-term growth projections [2]. - Napco attributed its declining hardware sales to one-off setbacks, while the complaint argues that the company's forecasting processes were inadequate [2]. Financial Impact - On February 3, 2025, Napco reported disappointing financial results for Q2 of fiscal 2025, showing a significant drop in hardware sales [3]. - Following this announcement, Napco's stock price fell from $36.70 per share on January 31, 2024, to $26.93 per share on February 3, 2025, marking a decline of approximately 26.62% in one day [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by June 24, 2025, but participation is not required to be eligible for recovery [4]. - The law firm Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5].